Heyuan Biotechnology (Tianjin) Co., Ltd.

Heyuan Biotechnology (Tianjin) Co. , Ltd. is a biotechnology company focused on developing and manufacturing innovative cell and gene therapies, particularly for hematological cancers through advanced CAR-T technology. Founded in 2018 and headquartered in Beijing, China, Heyuan Biotechnology (Tianjin) Co.

, Ltd. specializes in cell and gene therapy solutions. The company has successfully completed 4 funding deals, with its latest funding round, Series C, raised CNY 400 million on July 12, 2021. The funding aimed to enhance the commercialization of its proprietary CAR-T products and support the development of its advanced gene-editing technologies.

The CEO of the company is Lulu Lu. Heyuan Biotechnology (Tianjin) Co. , Ltd. primarily focuses on the development and manufacture of innovative cell and gene therapies.

Its flagship product, 源瑞达® (Inaticabtagene Autoleucel Injection, CNCT19), offers a breakthrough treatment for hematological malignancies, specifically targeting CD19 in leukemia patients. The therapy utilizes CAR-T cell technology to engineer patients' T cells to better combat cancer cells. Following its approval by the National Medical Products Administration (NMPA) in November 2023, the product is positioned to serve hospitals and medical institutions throughout China, with plans for future international expansion to regions with high demand for advanced cancer therapies. Heyuan Biotechnology (Tianjin) Co.

, Ltd. generates revenue through the commercialization of its CAR-T cell therapy, 源瑞达®. Sales occur via partnerships with healthcare institutions, allowing medical facilities to directly access the therapy for patients. This model ensures streamlined treatment pathways and includes collaborations with leading medical institutions, which may involve training programs for clinical application.

The pricing for 源瑞达® aligns with industry standards for advanced oncology treatments, reflecting the innovative nature of the therapies offered. Heyuan Biotechnology (Tianjin) Co. , Ltd. aims to expand its product portfolio by designing and launching new CAR-T therapies, leveraging the recent CNY 400 million funding to accelerate these initiatives.

The company plans to focus on international markets beginning in the next few years, targeting regions where advanced cancer therapies are in demand. The funding will also facilitate the rapid commercialization of their CAR-T products, enhancing their technology platforms, including CAR, iPSCs, and gene-editing technologies.